Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: PaulW who wrote (3744)	10/6/1999 4:20:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 10280

The ADRX/HOE deal is pretty uncompetitive on its face - basically HOE is paying ADRX handsomely to keep the generic off the market. (It's obviously more complicated than that because of the patent dispute, but that's still what a surface reading gives you). In contrast, the SEPR deal with LLY was the only way this improved drug could get to the market ahead of LLY's patent expiration. Thus it is arguably pro-competitive (unless of course you happen to be Barr, which wants to sell generic Prozac without competition from Prozac II). Peter